Hancock Whitney Corp Acquires 83,007 Shares of Halozyme Therapeutics, Inc. $HALO

Key Points

• Hancock Whitney Corp increased its stake in Halozyme Therapeutics by 68.7% during the first quarter, acquiring an additional 83,007 shares for a total of 203,818 shares valued at around $13 million.
• Several institutional investors have also recently made moves, with 97.79% of the company's stock now owned by such entities, indicating strong interest in the biopharmaceutical sector.
• In its latest earnings report, Halozyme Therapeutics beat expectations with an EPS of $1.54, exceeding the consensus estimate by $0.31 and reporting a 40.8% year-over-year revenue increase.

Hancock Whitney Corp raised its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 68.7% during the 1st quarter, according to its most recent filing with the SEC. The firm owned 203,818 shares of the biopharmaceutical company's stock after acquiring an additional 83,007 shares during the period. Hancock Whitney Corp owned approximately 0.17% of Halozyme Therapeutics worth $13,006,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the stock. Heck Capital Advisors LLC purchased a new position in shares of Halozyme Therapeutics during the fourth quarter valued at approximately $29,000. Wealth Preservation Advisors LLC bought a new stake in Halozyme Therapeutics in the 1st quarter worth approximately $32,000. SVB Wealth LLC bought a new stake in Halozyme Therapeutics in the 1st quarter worth approximately $33,000. Bessemer Group Inc. lifted its holdings in shares of Halozyme Therapeutics by 62.9% during the 1st quarter. Bessemer Group Inc. now owns 536 shares of the biopharmaceutical company's stock valued at $34,000 after buying an additional 207 shares during the period. Finally, Brooklyn Investment Group boosted its stake in shares of Halozyme Therapeutics by 1,558.1% in the 1st quarter. Brooklyn Investment Group now owns 713 shares of the biopharmaceutical company's stock worth $45,000 after buying an additional 670 shares during the last quarter. Hedge funds and other institutional investors own 97.79% of the company's stock.

Insider Buying and Selling at Halozyme Therapeutics

In related news, CEO Helen Torley sold 20,000 shares of the company's stock in a transaction on Tuesday, August 12th. The shares were sold at an average price of $63.51, for a total transaction of $1,270,200.00. Following the completion of the transaction, the chief executive officer owned 733,719 shares in the company, valued at approximately $46,598,493.69. This represents a 2.65% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Bernadette Connaughton sold 4,000 shares of the firm's stock in a transaction on Tuesday, September 2nd. The shares were sold at an average price of $73.68, for a total transaction of $294,720.00. Following the transaction, the director directly owned 46,952 shares of the company's stock, valued at $3,459,423.36. The trade was a 7.85% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 84,000 shares of company stock worth $4,827,320 in the last three months. Insiders own 2.90% of the company's stock.

Analyst Upgrades and Downgrades

HALO has been the subject of several research analyst reports. Wells Fargo & Company lifted their price objective on Halozyme Therapeutics from $60.00 to $65.00 and gave the stock an "equal weight" rating in a report on Wednesday, May 7th. Benchmark lowered shares of Halozyme Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, May 7th. Leerink Partners cut shares of Halozyme Therapeutics from a "market perform" rating to an "underperform" rating and set a $47.00 price objective on the stock. in a research note on Tuesday, May 13th. Zacks Research upgraded shares of Halozyme Therapeutics from a "hold" rating to a "strong-buy" rating in a research report on Tuesday. Finally, JMP Securities increased their price target on shares of Halozyme Therapeutics from $78.00 to $91.00 and gave the stock a "market outperform" rating in a research report on Wednesday, August 6th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, five have assigned a Hold rating and two have assigned a Sell rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Hold" and a consensus price target of $67.11.

Halozyme Therapeutics Stock Performance

NASDAQ HALO opened at $74.82 on Thursday. The company has a quick ratio of 7.01, a current ratio of 8.36 and a debt-to-equity ratio of 4.54. Halozyme Therapeutics, Inc. has a twelve month low of $42.01 and a twelve month high of $74.94. The business has a 50-day moving average price of $61.93 and a 200-day moving average price of $59.59. The firm has a market cap of $8.75 billion, a price-to-earnings ratio of 17.12, a price-to-earnings-growth ratio of 0.42 and a beta of 1.19.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last issued its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $1.54 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.23 by $0.31. Halozyme Therapeutics had a return on equity of 150.85% and a net margin of 47.28%.The company had revenue of $325.72 million for the quarter, compared to the consensus estimate of $282.66 million. During the same quarter last year, the company earned $0.91 EPS. The firm's quarterly revenue was up 40.8% on a year-over-year basis. Halozyme Therapeutics has set its FY 2025 guidance at 6.000-6.400 EPS. As a group, equities research analysts predict that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

Want to see what other hedge funds are holding HALO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.